This infographic highlights the key benefits of being a member of AMCP for managed care professionals (a.k.a. MCPs) in different career settings.
Chronic Kidney Disease Resources
Chronic Kidney Disease Resources
Chronic Kidney Disease is when the kidneys gradually get damaged over time and the kidneys are unable to complete functions such as removing wastes from your body, maintain blood pressure, and keeping your bones healthy.
Signs of chronic kidney disease include:
- Itchy or dry skin
- Nausea
- Weight loss
- Loss of appetite
- Fatigue
- Irregular urinating patterns
- Concentration issues
- Muscle cramps
- High blood pressure
Diseases and conditions that can cause chronic kidney disease include:
- Type 1 or 2 diabetes
- High blood pressure
- Obesity
- Heart disease
- Family history
- Glomerular diseases
- Inherited conditions
- Autoimmune conditions
- Severe infections
Treatment of chronic kidney disease:
- Following instructions when using medication
- Maintain healthy weight
- Avoid smoking
Journal of Managed Care + Specialty Pharmacy Publications
- Descriptive Study of the Economic Burden Among Patients With Type 2 Diabetes Mellitus, Chronic Kidney Disease, and Chronic Kidney Disease and Type 2 Diabetes Mellitus in a Large US Commercially Insured Population. Journal of Managed Care + Specialty, 2022, Dec;29(1):80-89.
- Costs Associated With the Administration of Erythropoiesis-Stimulating Agents for the Treatment of Anemia in Patients With Non-Dialysis-Dependent Chronic Kidney Disease: A US Societal Perspective. Journal of Managed Care + Specialty, 2021 Nov;27(11):1703-1713.
- Association of Dyskalemias With Short-Term Health Care Utilization in Patients With Advanced CKD. Journal of Managed Care + Specialty, 2021 Oct;27(10):1403-1415.
Additional Publications
- C3G and Ig-MPGN-Treatment Standard. Noris M, Remuzzi G. Nephrology, Dialysis, Transplantation, 2024, Jan. doi: 10.1093/ndt/gfad182.
- C3 Glomerulopathy: Understanding an Ultra-Rare Complement-Mediated Renal Disease. Heiderscheit A K, Hauer J J, Smith R J H. American Journal of Medical Genetics, 2022, Sep. doi: 10.1002/ajmg.c.31986.
- Clinico-Pathogenic Similarities and Differences Between Infection-Related Glomerulonephritis and C3 Glomerulopathy. Wada Y, Kamata M, Miyasaka, et al. Int J Mol Sci, 2023, May. doi: 10.3390/ijms24098432.
- Gain-of-Function Mutations R249C and S250C in Complement C2 Protein Increase C3 Deposition in the Presence of C-Reactive Protein. Urban A, Kowalska D, Stasilojc G, et al. Frontiers In Immunology, 2021, Nov. doi: 10.3389/fimmu.2021.724361.
- Developing Therapies for C3 Glomerulopathy: Report of the Kidney Health Initiative C3 Glomerulopathy Trial Endpoints Work Group. Nester C, Decker D A, Meier M, et al. Clinical Journal Of The American Society Of Nephrology, 2024, Jun. doi: 10.2215/CJN.0000000000000505.
Sponsored by Apellis
©2025 Apellis Pharmaceuticals, Inc. All rights reserved. 1/25 US-C3G-2500007 v1.0
Related
The Access to Prescription Digital Therapeutics Act of 2023 will help ensure that the greatest number of patients possible are receiving innovative, modern care, which is especially vital for closing care gaps caused by specialist shortages or geographic obstacles. View the issue brief to learn more.
The Kidney Health Initiative convened a panel of experts in C3G to (1) assess the data supporting the use of the prespecified trial end points as measures of clinical benefit and (2) opine on efficacy findings they would consider compelling as treatment(s) of C3G in native kidneys. View the findings.
Upcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
